Calls Grow for Immediate Enforcement as Unapproved Knockoffs Flood Market WASHINGTON, D.C. — July 22, 2025: A new report from The Center for Medicine in the Public Interest (CMPI) warns that regulators are failing to stop the illegal mass production of compounded GLP-1 drugs despite mounting evidence of patient harm and urges the U.S. [...]
Sherlyn Celone-Arnold assumes new role after successful run as Chief Strategy Officer ROCKVILLE, MD – The Obesity Society (TOS), the leading organization of scientists and health professionals devoted to understanding and reversing the epidemic of obesity, has announced Sherlyn Celone-Arnold, M.S., as its new CEO, following the retirement of her predecessor, Anthony Comuzzie, Ph.D., [...]
Evidence-based nutrition and lifestyle interventions enhance GLP-1 treatment outcomes for obesity, improving adherence, health gains, and long-term weight maintenance Washington, D.C. (May 30, 2025) – Four leading organizations in lifestyle medicine, obesity medicine, and nutrition—the American College of Lifestyle Medicine (ACLM), the American Society for Nutrition (ASN), the Obesity Medicine Association (OMA), and The [...]
Click here to learn more.
ROCKVILLE, MD-Advances in evidence-based obesity medications and treatment options are critical for the millions of individuals living with the chronic disease. The Obesity Society is encouraged by the development of new options that are effective, safe, and convenient for consumers. Last week, results released for the ACHIEVE-1 Phase 3 clinical trial suggest that a [...]
Rockville, Md. – The Obesity Society is disappointed with the decision made by the Centers for Medicare and Medicaid Services (CMS) to continue its policy that restricts access to safe and effective obesity medications. The announcement that CMS will reject Part D coverage of obesity medications and application to the Medicaid program in a [...]
March 19, 2025 — Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading organizations and providers across the healthcare continuum, urging the agency to enforce federal regulations around compounding following the recent resolution of GLP-1 medicine shortages. [...]
ROCKVILLE, MD – The Obesity Society (TOS) acknowledges the U.S. Food and Drug Administration's (FDA) recent announcement declaring the end of shortages for Novo Nordisk's Wegovy and Ozempic; two critical medications in the treatment of obesity and diabetes. This development signifies a pivotal advancement in patient care, ensuring broader access to these essential, FDA-approved [...]
Rockville, Md. -- A Super Bowl advertisement by Hims & Hers, a consumer health and wellness platform, will mislead viewers by excluding any information about the overall risks and side effects of compounded drugs. The ad emphasizes the role of the food and health system in the obesity epidemic and fails to include any [...]
ROCKVILLE, Md. -- The Obesity Society (TOS) applauds the work of The Lancet Diabetes & Endocrinology Commission on Diagnostic Criteria of Clinical Obesity to refine the definition of obesity and establish a framework for diagnosing other chronic diseases caused by excess adiposity. Several prominent experts in obesity and related metabolic diseases who are members [...]